• 1
    Smith LL. Cholesterol Autoxidation. New York: Plenum Press, 1981.
  • 2
    Lund E, Diczfalusy U, Björkhem I. On the mechanism of oxidation of cholesterol at C-7 in a lipoxygenase system. J Biol Chem 1992; 267: 1246267.
  • 3
    Russell DW. Oxysterol biosynthetic enzymes. Biochim Biophys Acta 2000; 1529: 12635.
  • 4
    Dzeletovic S, Breuer O, Lund E, Diczfalusy U. Determination of cholesterol oxidation products in human plasma by isotope dilution-mass spectrometry. Anal Biochem 1995; 225: 7380.
  • 5
    Breuer O. Identification and quantitation of cholest-5-ene-3β,4β-diol in rat liver and human plasma. J Lipid Res 1995; 36: 227581.
  • 6
    Brooks CJW, Cole WJ. Some aspects of the analysis of minor oxygenated sterols in serum and in serum lipoprotein fractions. J Am Oil Chem Soc 1985; 62: 622.
  • 7
    Breuer O, Björkhem I. Use of an 18O2 inhalation technique and mass isotopomer distribution analysis to study oxygenation of cholesterol in rat. Evidence for in vivo formation of 7-oxo-, 7β-hydroxy-, 24-hydroxy-, and 25-hydroxycholesterol. J Biol Chem 1995; 270: 2027884.
  • 8
    Breuer O, Dzeletovic S, Lund E, Diczfalusy U. The oxysterols cholest-5-ene-3β,4α-diol, cholest-5-ene-3β,4β-diol and cholestane-3β,5α,6α-triol are formed during in vitro oxidation of low density lipoprotein, and are present in human atherosclerotic plaques. Biochim Biophys Acta 1996; 1302: 14552.
  • 9
    Bodin K, Bretillon L, Aden Y, Bertilsson L, Broomé U, Einarsson C, Diczfalusy U. Antiepileptic drugs increase plasma levels of 4β-hydroxycholesterol in humans. Evidence for involvement of cytochrome P450 3A4. J Biol Chem 2001; 276: 3868589.
  • 10
    Bertilsson L, Höjer B, Tybring G, Osterloh J, Rane A. Autoinduction of carbamazepine metabolism in children by a stable isotope technique. Clin Pharmacol Ther 1980; 27: 838.
  • 11
    Bodin K, Andersson U, Rystedt E, Ellis E, Norlin M, Pikuleva I, Eggertsen G, Björkhem I, Diczfalusy U. Metabolism of 4β-hydroxycholesterol in humans. J Biol Chem 2002; 277: 3153440.
  • 12
    Eichelbaum M, Burk O. CYP3A genetics in drug metabolism. Nat Med 2001; 7: 28587.
  • 13
    Galteau MM, Shamsa F. Urinary 6β-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur J Clin Pharmacol 2003; 59: 71333.
  • 14
    Mirghani RA, Ericsson O, Tybring G, Gustafsson LL, Bertilsson L. Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man. Eur J Clin Pharmacol 2003; 59: 238.
  • 15
    Mirghani RA, Sayi J, Aklillu E, Allqvist A, Jande M, Wennerholm A, Ericksen J, Herben VMM, Jones BC, Gustafsson LL, Bertilsson L. CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population. Pharmacogenet Genomics 2006; 16: 63745.
  • 16
    Diczfalusy U, Miura J, Roh H-K, Mirghani RA, Sayi J, Larsson H, Bodin KG, Allqvist A, Jande M, Kim J-W, Aklillu E, Gustafsson LL, Bertilsson L. 4β-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet Genomics 2008; 18: 20108.
  • 17
    Hulst LK, Fleishaker JC, Peters GR, Harry JD, Wright DM, Ward P. Effect of age and gender on tirilazad pharmacokinetics in humans. Clin Pharmacol Ther 1994; 55: 37884.
  • 18
    Gebeyehu E, Engidawork E, Bijnsdorp A, Aminy A, Diczfalusy U, Aklillu E. Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians. Pharmacogenom J 2010; doi:10.1038/tpj.2010.16.
  • 19
    Tomalik-Scharte D, Lütjohann D, Doroshyenko O, Frank D, Jetter A, Fuhr U. Plasma 4β-hydroxycholesterol: an endogenous CYP3A metric? Clin Pharmacol Ther 2009; 86: 14753.
  • 20
    Wide K, Larsson H, Bertilsson L, Diczfalusy U. Time course of the increase in 4β-hydroxycholesterol concentration during carbamazepine treatment of pediatric patients with epilepsy. Br J Clin Pharmacol 2008; 65: 70815.
  • 21
    Kanebratt KP, Diczfalusy U, Bäckström T, Sparve E, Bredberg E, Böttiger Y, Andersson TB, Bertilsson L. Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4β-hydroxycholesterol. Clin Pharmacol Ther 2008; 84: 58994.
  • 22
    Christensen M, Andersson K, Dalén P, Mirghani RA, Muirhead GJ, Nordmark A, Tybring G, Wahlberg A. Yasar Ü, Bertilsson L. The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin Pharmacol Ther 2003; 73: 51728.
  • 23
    Niemi M, Kivistö KT, Diczfalusy U, Bodin K, Bertilsson L, Fromm MF, Eichelbaum M. Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampin. Pharmacogenet Genomics 2006; 16: 56568.
  • 24
    Josephson F, Bertilsson L, Böttiger Y, Flamholc L, Gisslén M, Ormaasen V, Sönnerborg A, Diczfalusy U. CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasama 4β-hydroxycholesterol. Eur J Clin Pharmacol 2008; 64: 77581.
  • 25
    Lütjohann D, Marinova M, Schneider B, Oldenburg J, von Bergmann K, Bieber T, Björkhem I, Diczfalusy U. 4β-hydroxycholesterol as a marker of CYP3A4 inhibition in vivo – effects of itraconazole in man. Int J Clin Pharmacol Ther 2009; 47: 70915.
  • 26
    Diczfalusy U, Kanebratt KP, Bredberg E, Andersson TB, Böttiger Y, Bertilsson L. 4β-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin. Br J Clin Pharmacol 2009; 67: 3843.
  • 27
    Kinirons MT, O'Shea D, Kim RB, Groopman JD, Thummel KE, Wood AJ, Wilkinson GR. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clin Pharmacol Ther 1999; 66: 22431.
  • 28
    Masica AL, Mayo G, Wilkinson GR. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. Clin Pharmacol Ther 2004; 76: 3419.
  • 29
    Yang Z, Rodrigues AD. Does the long plasma half-life of 4β-hydroxycholesterol impact on its utility as a cytochrome P450 3A (CYP3A) metric? J Clin Pharmacol 2010; doi:10.1177/0091270009360041.